Tyrosine News and Research

RSS

AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates for COVID-19

AI VIVO has announced that it is seeking pharma and biotech collaboration partners to progress therapeutic candidates for COVID-19.

11 May 2020

Drug combo for untreated CLL approved by FDA based on E1912 trial

Patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma now have a new treatment option--a combination of the targeted agent ibrutinib with the immunologic agent rituximab.

29 Apr 2020

Research provides insights into how Zika virus can spread through sexual contact

Zika virus is capable of replicating and spreading infectious particles within the outermost cells lining the vaginal tract, according to new research. The findings provide the first molecular-level insights into how the virus can move from person to person through sexual contact.

27 Apr 2020

Specialized proteins could soak up excess cytokines in COVID-19 patients

One of the defining features of Covid-19 is the excessive immune response that can occur in severe cases. This burst of immune overreaction, also called a cytokine storm, damages the lungs and can be fatal.

16 Apr 2020

Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

1 Apr 2020

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly monitored during the first month of therapy.

22 Mar 2020

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.

21 Mar 2020

Singapore researchers find common therapeutic vulnerability for a deadly blood cancer

CML is a blood cancer that can be controlled by continuously taking an expensive type of medicine called a tyrosine kinase inhibitor (TKI). In almost all patients, stopping TKI treatment results in recurrence of CML.

18 Mar 2020

Engineered botox more effective

A new study reports on an engineered botulinum neurotoxin (botox) that is more effective as well as safer to use in various medical procedures. The study was published in March 2020 in the open-access journal PLOS Biology.

17 Mar 2020

Novel drug combination discovered to induce high rates of human beta cell proliferation

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a novel combination of two classes of drugs that, together, cause the highest rate of proliferation ever observed in adult human beta cells- the cells in the pancreas that produce insulin- without harming most other cells in the body.

12 Feb 2020

KAIST researchers identify mechanism that fuels a 'domino effect' in cancer drug resistance

KAIST researchers have identified mechanisms that relay prior acquired resistance to the first-line chemotherapy to the second-line targeted therapy, fueling a "domino effect" in cancer drug resistance.

11 Feb 2020

Researchers reveal new activity above the surface in brain-cell receptors

Like buoys bobbing on the ocean, many receptors float on the surface of a cell's membrane with a part sticking above the water and another underwater, inside the cell's cytoplasm.

7 Feb 2020

Study may help develop ibrutinib-based combination therapies for blood cancer

Chronic lymphocytic leukemia (CLL) is the most common form of blood cancer (leukemia) in the Western world, affecting approximately 1.2% of all cancer patients.

30 Jan 2020

Report highlights steady 26-year decline in overall cancer mortality

The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

8 Jan 2020

Inhibition of a single enzyme may reduce heparin-induced thrombocytopenia

Heparin is widely used as an anticoagulant, but evokes in some patients a potentially life-threatening condition called HIT. Clinical scientists at Ludwig-Maximilians-Universitaet in Munich have now shown that inhibition of a single enzyme may markedly reduce this risk.

21 Dec 2019

Cancer drug shows promise in battling Parkinson’s disease

Parkinson’s disease (PD) is a lifelong condition that affects the nerve cells in the brain that produce dopamine. As a result, people with this neurodegenerative disease experience tremors, changes in speech, gait issues, and muscle rigidity. Though it has no cure, a new drug used to treat cancer shows promise in treating Parkinson’s.

17 Dec 2019

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

A clinical trial investigating the repurposed cancer drug nilotinib in people with Parkinson's disease finds that it is reasonably safe and well tolerated.

17 Dec 2019

The sympathetic nervous system can modulate action of defense cells in autoimmune disease

The results of a study conducted in Brazil suggest that the sympathetic nervous system - the part of the autonomous nervous system that controls responses to danger or stress - can modulate the action of defense cells in patients with autoimmune diseases.

16 Dec 2019

Research reveals how skeletal muscle communicates with the brain regarding feeding behavior

The brain determines when it is time to feed - but how does it know? Findings from St. Jude Children's Research Hospital provide new understanding of how the brain orchestrates this process.

12 Dec 2019

Treatment combination improves survival in advanced HER2-positive breast cancer patients

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

11 Dec 2019